The US Food and Drug Administration (FDA) opened a new path in digital medicine in 2017, approving the first "digital pill", the Abilify MyCiteIt is a medicine that combines pharmaceutical action with digital technology: one biosensor embedded in the tablet itself, which can inform doctors and caregivers about whether and when the patient took it.
Abilify MyCite is intended for patients with schizophrenia, bipolar disorder and depressionThe tiny sensor is activated in the stomach and sends a signal via Bluetooth to a plaster and from there to mobile application, providing information on medication compliance.
Why is it now back in the news?
Although the initial approval was made in 2017, the topic of the "smart pill" returns strongly to the public in 2025, for reasons related to:
✔️ New approvals or extensions of indications – Possible use in more diseases or in new age groups.
✔️ Reset due to technological developments – Telemedicine platforms and new applications are rekindling interest.
✔️ International circulation – The technology may be released in new markets outside the US.
✔️ Renewed social and journalistic debate – Concerns about resurfacing privacy and ethics.
✔️ Use in new research projects or pilot applications in hospitals and health centers.
Advantages and caveats
The digital pill may prove lifesaving in cases low compliance with medication. However, there is also no shortage of reactions, mainly for issues protection of personal data and technological control the patients.
Sources & Information:
-
FDA.gov – Official approval announcement (2017)
-
NPR – “First Digital Pill Approved”
-
Google News – Updated references to Abilify MyCite (2025)
From the editorial team of Greek News and Radio FL
photo HeungSoon, https://pixabay.com
